Oral Solid Dosage Contract Manufacturing Market is Expected to Reach a Valuation of US$ 40,776.0 Million by 2034 | Fact.MR Report

Rising Prevalence of Chronic Diseases Spurs Demand for Oral Solid Dosage Formulations, Compelling Market Growth

/EIN News/ -- Rockville, MD, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The global oral solid dosage contract manufacturing market size is projected to reach US$ 26,457.9 million in 2024. The sales of oral solid dosage contract manufacturing are expected to witness a CAGR of 4.4% from 2024 to 2034. By 2034, the demand for oral solid dosage contract manufacturing is anticipated to attain a valuation of US$ 40,776.0 million.

The growth in the US FDA-approved manufacturing facilities is a key driver propelling the market expansion. China and India hold a dominant position in the OSD contract manufacturing business. With 400 manufacturing facilities recognized by the US FDA, India is one of the popular destinations for outsourcing contract manufacturing services related to oral solid dosage.

Many industrial facilities are approved in other nations, such as China, India, Mexico, and Brazil. Many international OSD manufacturing firms are outsourcing their production to CMOs in China, contributing to the growth of CMOs. It is anticipated that these variables ought to have a beneficial effect on oral solid dosage contract manufacturing market growth, which propels the global market.

The primary factor that causes capacity limitations is the small and mid-sized authorized manufacturing facilities. The absence of young, skilled scientists, technicians, and production workers, the scarcity of reasonably priced single-use goods, and the limitations of improved upstream performance are additional issues that have a significant impact on the constraints in the oral solid dosage contract manufacturing market. During the forecast period, these difficulties hinder oral solid dosage contract manufacturing market growth.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9634

Regional Outlook

Due to the region's dedication to pharmaceutical excellence, oral solid dosage contract manufacturing is a vibrant industry in North America. The oral solid dosage contract manufacturing industry is driven by a high demand for customized formulations and a focus on quality assurance. 

Research and development investments are rising as the pharmaceutical sector expands in nations like China and India, positioning Asia Pacific as a leading hub for oral solid dosage contract manufacturing.

Oral solid dosage contract manufacturing in Europe has steadily expanded due to the region's concentration on innovation and technology adoption in pharmaceutical manufacturing techniques.

“The demand for flexible manufacturing solutions, cost-effective production, and growing outsourcing tendencies contribute to the oral solid dosage contract manufacturing market growth. Pharmaceutical firms face a competitive landscape shaped by economic conditions, such as technical breakthroughs, regulatory compliance, and strategic collaborations.” says an analyst

Key Takeaways 

• The tablets segment in the prescription type category to grab a share of 9% by 2034.
• In the disintegration type category, the tablets segment to acquire a market share of 9% by 2034.
• The tablets segment in the disintegration type category exhibits a CAGR of 9% from 2024 to 2034.
• In the prescription type category, the tablets segment to accelerate at a CAGR of 9% between 2024 and 2034.
• The United States oral solid dosage contract manufacturing sales are anticipated to surge at a CAGR of 4% from 2024 to 2034.
• Canada oral solid dosage contract manufacturing market to develop at a CAGR of 2% through 2034.
• Mexico oral solid dosage contract manufacturing industry is anticipated to surge at a CAGR of 3% between 2024 and 2034.
• China oral solid dosage contract manufacturing sales are expected to surge at a CAGR of 4% through 2034.
• South Korea oral solid dosage contract manufacturing industry is anticipated to boost at a CAGR of 1% between 2024 and 2034.
• Japan oral solid dosage contract manufacturing market to exhibit a CAGR of 5% through 2034.

Leading Players Driving Innovation in the Oral Solid Dosage Contract Manufacturing Market:

Key players in the oral solid dosage contract manufacturing market include Recipharm, Aenova Holding, Catalent, AbbVie, Patheon N.V. (Thermo Fisher Scientific), NextPharma, Capsugel (Lonza Group AG), Aurobindo Pharma Limited, Siegfried AG, Piramal Pharma Solutions, Corden Pharma, Kremoint Pharma Pvt Ltd., HERMES PHARMA GmbH, Medipaams, India Private Limited, Alpex Pharma, Abaris Healthcare Pvt Ltd, Ardena Holdings N.V, Aphena Pharma Solutions, Actiza Pharmaceutical Private Limited, Sunwin Healthcare PVT. LTD, Saffron Medicare PVT. LTD, Kosher Pharmaceuticals, Dr Reddy’s Lab, GlaxoSmithKline Plc, and Boehringer Ingelheim BioXcellence.

Competitive Landscape:

The oral solid dosage contract manufacturing manufacturers are concentrating on expanding their manufacturing units due to the growing demand for pharmaceutical manufacturing. Important oral solid dosage contract manufacturing suppliers have developed and acquired businesses to strengthen their position in the industry.

• A US$ 175 million investment was announced in May 2022 by Catalent, Inc. to expand its flagship large-scale oral dose form manufacturing facility in Winchester, Kentucky.
• One of the top CDMOs, Piramal Pharma Solutions (PPS), announced in June 2019 the grand opening of a new wing at the Riverview facility devoted to producing High Potency Active Pharmaceutical Ingredients (HPAPIs) with Low Occupational Exposure Levels (OELs).

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9634

Oral Solid Dosage Contract Manufacturing Industry News:

• A contract manufacturing services agreement for Gilead's experimental antiviral medication, Remdesivir, was announced in August 2020 by Pfizer Inc. and Gilead Sciences, Inc. Increased access to experimental treatment for COVID-19 patients is the aim of this partnership.
• In January 2023, the Aenova Group expanded its capacity to fill capsules at its Regensburg facility by installing the state-of-the-art IMA Adapta 200 machine.

Check out More Related Studies Published by Fact.MR:

Shower Chair Market: Size is estimated to reach US$ 5.14 billion and is forecasted to expand at a CAGR of 9% to reach US$ 12.21 billion by 2034.

Home DNA Testing Market: Size is expected to grow at a compound annual growth rate (CAGR) of 16.3%, from a 2024 valuation of US$ 4.62 billion to a 2034 valuation of US$ 20.96 billion.

Particle-Enhanced Turbidimetric Immunoassay Market: Size is estimated at US$ 2.03 billion in 2024. The market is further projected to increase at a CAGR of 9.6% to touch a value of US$ 5.05 billion by 2034.

In Vitro Diagnostics Test Kit Market: Size is estimated to stand at US$ 12.35 billion in 2024 and is evaluated to increase at a CAGR of 6.4% to reach US$ 22.93 billion by 2034.

Therapeutic Support Surface Market: Size is expected to grow at a compound annual growth rate (CAGR) of 7.6%, from a 2024 valuation of US$5.5 billion to a 2034 valuation of US$11.4 billion.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | Blog